今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

余承东回应“20万以下车”：华为暂不考虑，聚焦30万以上市场

北京报道 - 6月14日，在2024第十六届中国汽车蓝皮书论坛上，华为常务董事余承东针对华为汽车业务的未来发展作出了回应。他表示，华为目前没有能力推出20万元以下的汽车，并将继续聚焦30万元以上的高端市场。

余承东坦诚地表示，华为在汽车制造方面仍处于起步阶段，尚缺乏在低成本车型领域的核心竞争力。他指出，20万元以下车型的利润空间有限，需要强大的规模效应才能盈利。而华为目前尚未具备足够的销量基础，因此贸然进入这一市场可能会遭遇亏损。

聚焦高端市场，打造差异化竞争

尽管暂缓进入20万元以下市场，但余承东依然对华为汽车的未来充满信心。他强调，华为将继续聚焦30万元以上的高端市场，并通过创新技术和差异化服务，打造具有竞争力的产品。

具体而言，华为将重点围绕智能化、自动驾驶等领域进行技术攻关，为用户提供更加安全、舒适的驾乘体验。此外，华为还将积极拓展汽车生态链，打造“车、家、生态”的数字生活体验。

“余大嘴”的务实转身

余承东一直以其敢言敢行的风格著称，也因此得到了“余大嘴”的绰号。然而，在汽车业务上，余承东却展现出了更加务实的一面。他坦言华为的不足，并明确了未来的发展方向，这体现了一位成熟企业家的责任感和担当。

分析人士认为，华为聚焦高端市场的策略是明智的。 一方面，高端市场利润更高，能够为企业带来更大的收益；另一方面，高端市场也更容易树立品牌形象，提升品牌影响力。

华为能否在高端汽车市场取得成功还有待观察，但其务实的态度和坚定的决心值得肯定。 随着汽车产业的不断变革，华为能否抓住机遇，实现弯道超车，让我们拭目以待。